• Secured first U.S. commercial customers and generated first U.S. commercial revenues
• Achieved FDA 510(k) clearance for Salix® Coronary Plaque module
• Completed A$80 million capital raise to support U.S. commercialisation and development

Artrya Limited reported a loss of $10.743 million for the half-year ended 31 December 2025, up 44.4% from the prior period. The company was focused on the commercialisation and development of its Salix® suite of cloud-based software products, including securing the first U.S. commercial customers and generating the first U.S. commercial revenues during the half-year. A major milestone was achieved with FDA 510(k) clearance for the Salix® Coronary Plaque module, which enables real-time detection of high-risk coronary plaque and integrates with the FDA-cleared Salix® Coronary Anatomy platform. Artrya also made strong commercial progress, with three U.S. foundation partners - Tanner Health, Northeast Georgia Health System, and Cone Health - becoming commercial customers under long-term agreements. The company also advanced the SAPPHIRE Study, securing agreement from six high-volume U.S. hospital systems to participate. Development of the Salix® Coronary Flow module remained a key priority, with plans to lodge a 510(k) submission in 2026. Artrya completed an A$80 million capital raise to support U.S. commercialisation, regulatory programs, and operational scale-up.

The company estimates a $5.6 million R&D refund for the 2025 financial year.